The Study of Bacteriology and Pathogen Drug Sensitivity of Chronic Dacryocystitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03216642|
Recruitment Status : Unknown
Verified July 2017 by Wang Zhichong, Sun Yat-sen University.
Recruitment status was: Recruiting
First Posted : July 13, 2017
Last Update Posted : July 27, 2017
|Condition or disease||Intervention/treatment|
|Dacryocystitis Bacteriology||Diagnostic Test: bacterial culture and analysis|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||100 participants|
|Target Follow-Up Duration:||2 Months|
|Official Title:||The Study of Bacteriology and Pathogen Drug Sensitivity of Chronic Dacryocystitis|
|Actual Study Start Date :||July 17, 2017|
|Estimated Primary Completion Date :||April 17, 2018|
|Estimated Study Completion Date :||April 17, 2018|
- Diagnostic Test: bacterial culture and analysis
Specimens were collected with soft-tipped applicators of sterile cotton swabs after syphilis of lacrimal passages.Other Name: antibiotic susceptibility
- Bacterial agents [ Time Frame: 2 weeks ]Specimens will be collected after irrigation of the lacrimal passage and be sent for bacterial culture and bacterial analysis.
- Sensitivity test [ Time Frame: 2 weeks ]The drugs tested include Penicilin, Amikacin, Azithromycin, Cefoxitin, Levofloxacin，Ofloxacin, Cefuroxime and Tobramycin.
- The colour of lacrimal sac secretion [ Time Frame: 2 weeks ]The colour of lacrimal sac secretion will be identified by the doctor during the irrigation of the lacrimal passage.
- The character of lacrimal sac secretion [ Time Frame: 2 weeks ]The lacrimal sac secretion will be classified as mucus or pus.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03216642
|Contact: Zhang Xiulan, M.D.||email@example.com|
|Clinical Research Center||Recruiting|
|Guangzhou, Guangdong, China, 510000|
|Contact: Wang Zhichong, M.D. 02087333391 firstname.lastname@example.org|
|Contact: Liu Chengxiu 02087333391 email@example.com|